JP2013527232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013527232A5 JP2013527232A5 JP2013513207A JP2013513207A JP2013527232A5 JP 2013527232 A5 JP2013527232 A5 JP 2013527232A5 JP 2013513207 A JP2013513207 A JP 2013513207A JP 2013513207 A JP2013513207 A JP 2013513207A JP 2013527232 A5 JP2013527232 A5 JP 2013527232A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- bladder cancer
- administered
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 48
- 206010005003 Bladder cancer Diseases 0.000 claims 17
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 14
- 201000005112 urinary bladder cancer Diseases 0.000 claims 14
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 10
- 239000002105 nanoparticle Substances 0.000 claims 6
- 102000009027 Albumins Human genes 0.000 claims 5
- 108010088751 Albumins Proteins 0.000 claims 5
- 229910052697 platinum Inorganic materials 0.000 claims 5
- 229940123237 Taxane Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39680010P | 2010-06-02 | 2010-06-02 | |
| US61/396,800 | 2010-06-02 | ||
| US201161449513P | 2011-03-04 | 2011-03-04 | |
| US61/449,513 | 2011-03-04 | ||
| PCT/US2011/037449 WO2011153009A1 (en) | 2010-06-02 | 2011-05-20 | Methods of treating bladder cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013527232A JP2013527232A (ja) | 2013-06-27 |
| JP2013527232A5 true JP2013527232A5 (enExample) | 2014-07-03 |
Family
ID=45067028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513207A Pending JP2013527232A (ja) | 2010-06-02 | 2011-05-20 | 膀胱がんの処置方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20130266659A1 (enExample) |
| EP (1) | EP2575803B1 (enExample) |
| JP (1) | JP2013527232A (enExample) |
| KR (1) | KR20130109025A (enExample) |
| CN (1) | CN103221042B (enExample) |
| AU (1) | AU2011261684B2 (enExample) |
| BR (1) | BR112012030699A2 (enExample) |
| CA (1) | CA2801314A1 (enExample) |
| CO (1) | CO6620019A2 (enExample) |
| CR (1) | CR20120619A (enExample) |
| ES (1) | ES2639038T3 (enExample) |
| MX (1) | MX343671B (enExample) |
| MY (1) | MY188911A (enExample) |
| NI (1) | NI201200175A (enExample) |
| NZ (2) | NZ708506A (enExample) |
| PH (2) | PH12012502378A1 (enExample) |
| RU (1) | RU2621640C2 (enExample) |
| SG (1) | SG186109A1 (enExample) |
| WO (1) | WO2011153009A1 (enExample) |
| ZA (1) | ZA201208815B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| SG166775A1 (en) | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE042678T2 (hu) * | 2005-08-31 | 2019-07-29 | Abraxis Bioscience Llc | Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek |
| JP5933893B2 (ja) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス， エルエルシー | ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法 |
| CA3201293A1 (en) * | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
| HRP20160609T1 (hr) | 2010-03-26 | 2016-09-23 | Abraxis Bioscience, Llc | Postupci liječenja hepatocelularnog karcinoma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| KR102315754B1 (ko) | 2010-05-14 | 2021-10-22 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| NZ707377A (en) * | 2010-06-07 | 2015-09-25 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
| KR101970342B1 (ko) | 2011-04-28 | 2019-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| DK177379B1 (en) * | 2012-03-29 | 2013-02-25 | Entomopharm Aps | Insect-based model to study the effect and integrity of nanoparticles on blood-brain barrier function |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140199404A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CA2903454A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| KR20150126671A (ko) * | 2013-03-13 | 2015-11-12 | 아브락시스 바이오사이언스, 엘엘씨 | 소아 고형 종양의 치료 방법 |
| EP2968191B1 (en) * | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| WO2015018380A2 (en) * | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Therapeutic nanoparticles and the preparation methods thereof |
| WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
| WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| CR20200476A (es) | 2015-05-20 | 2020-12-02 | Dana Farber Cancer Inst Inc | ANTÍGENOS COMPARTIDOS (Divisional 2017-0584) |
| CA3026454C (en) | 2015-06-04 | 2023-07-04 | Crititech, Inc. | Collection device and methods for use |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| HK1254398A1 (zh) * | 2015-06-29 | 2019-07-19 | Abraxis Bioscience, Llc | 納米粒子組合物的生物標誌物 |
| CA2994161A1 (en) * | 2015-07-31 | 2017-02-09 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| BR112018069628A2 (pt) | 2016-04-04 | 2019-02-12 | Crititech, Inc. | métodos para tratamento de tumor sólido |
| ES2940227T3 (es) * | 2016-05-06 | 2023-05-04 | Taris Biomedical Llc | Método de tratamiento del cáncer urotelial del tracto inferior |
| WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| JP7457642B2 (ja) | 2017-04-03 | 2024-03-28 | ビオンテック ユーエス インコーポレイテッド | タンパク質抗原およびその使用 |
| SG11201909840TA (en) | 2017-06-09 | 2019-11-28 | Crititech Inc | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
| KR102303762B1 (ko) | 2017-06-14 | 2021-09-23 | 크리티테크, 인크. | 폐 장애의 치료 방법 |
| WO2019023388A1 (en) | 2017-07-25 | 2019-01-31 | Taris Biomedical Llc | METHODS OF TREATING TUMOR METASTASIS |
| WO2019070850A1 (en) | 2017-10-03 | 2019-04-11 | Crititech, Inc. | LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
| PE20210041A1 (es) | 2017-11-08 | 2021-01-08 | Taris Biomedical Llc | Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| KR20200106911A (ko) * | 2018-01-05 | 2020-09-15 | 크리티테크, 인크. | 탁산 입자의 국소 투여에 의한 방광암의 치료 |
| EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
| CA3103983A1 (en) | 2018-06-19 | 2019-12-26 | Biontech Us Inc. | Neoantigens and uses thereof |
| WO2020072090A1 (en) * | 2018-10-03 | 2020-04-09 | Crititech, Inc. | Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls) |
| EP4051241A4 (en) | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
| WO2024102620A2 (en) * | 2022-11-09 | 2024-05-16 | Tempest Therapeutics, Inc. | Triazolone compounds and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| NZ268326A (en) * | 1993-07-19 | 1997-12-19 | Angiogenesis Tech Inc | Stent with a coating comprising an anti-angiogenic compound, such as taxol, and a polymeric carrier |
| GB9811598D0 (en) * | 1998-05-30 | 1998-07-29 | Imp College Innovations Ltd | Diagnosis and treatment of cancer |
| RU2361615C2 (ru) * | 2002-12-09 | 2009-07-20 | Абраксис Байосайенс, Ллс. | Композиции и способы доставки фармакологических агентов |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| SG166775A1 (en) * | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8034765B2 (en) | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| AU2008240117B2 (en) * | 2007-04-13 | 2013-12-05 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| EP2367425B1 (en) * | 2008-12-11 | 2018-02-28 | Abraxis BioScience, LLC | Combination therapy including a taxane and a further therapeutic agent |
| SG178873A1 (en) * | 2009-08-25 | 2012-04-27 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
-
2011
- 2011-05-20 WO PCT/US2011/037449 patent/WO2011153009A1/en not_active Ceased
- 2011-05-20 MX MX2012013909A patent/MX343671B/es active IP Right Grant
- 2011-05-20 NZ NZ708506A patent/NZ708506A/en unknown
- 2011-05-20 BR BR112012030699A patent/BR112012030699A2/pt not_active Application Discontinuation
- 2011-05-20 CA CA2801314A patent/CA2801314A1/en not_active Abandoned
- 2011-05-20 JP JP2013513207A patent/JP2013527232A/ja active Pending
- 2011-05-20 AU AU2011261684A patent/AU2011261684B2/en active Active
- 2011-05-20 KR KR1020127034199A patent/KR20130109025A/ko not_active Ceased
- 2011-05-20 ES ES11790192.6T patent/ES2639038T3/es active Active
- 2011-05-20 MY MYPI2012005167A patent/MY188911A/en unknown
- 2011-05-20 NZ NZ604029A patent/NZ604029A/en unknown
- 2011-05-20 CN CN201180038029.3A patent/CN103221042B/zh active Active
- 2011-05-20 US US13/701,003 patent/US20130266659A1/en not_active Abandoned
- 2011-05-20 EP EP11790192.6A patent/EP2575803B1/en not_active Revoked
- 2011-05-20 SG SG2012088019A patent/SG186109A1/en unknown
- 2011-05-20 RU RU2012157805A patent/RU2621640C2/ru active
- 2011-05-20 PH PH1/2012/502378A patent/PH12012502378A1/en unknown
-
2012
- 2012-11-22 ZA ZA2012/08815A patent/ZA201208815B/en unknown
- 2012-11-30 NI NI201200175A patent/NI201200175A/es unknown
- 2012-12-10 CR CR20120619A patent/CR20120619A/es unknown
- 2012-12-28 CO CO12236221A patent/CO6620019A2/es unknown
-
2013
- 2013-03-01 US US13/782,984 patent/US20140056986A1/en not_active Abandoned
-
2016
- 2016-10-18 PH PH12016502066A patent/PH12016502066A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013527232A5 (enExample) | ||
| JP2011079858A5 (enExample) | ||
| JP2013503174A5 (enExample) | ||
| RU2012157805A (ru) | Способы лечения рака мочевого пузыря | |
| JP2012520323A5 (enExample) | ||
| JP2013527233A5 (enExample) | ||
| JP2016513657A5 (enExample) | ||
| Aditya et al. | Advances in nanomedicines for malaria treatment | |
| JP2012506448A5 (enExample) | ||
| JP2017025090A5 (enExample) | ||
| 胡兴胜 et al. | 培美曲塞及吉西他滨分别联合顺铂治疗初治晚期非小细胞肺癌安全性和有效性的随机对照研究 | |
| JP2010180210A5 (enExample) | ||
| JP2011515481A5 (enExample) | ||
| JP2014532704A5 (enExample) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2017214436A5 (enExample) | ||
| JP2015515475A5 (enExample) | ||
| JP2010529025A5 (enExample) | ||
| JP2010509331A5 (enExample) | ||
| JP2008530248A5 (enExample) | ||
| JP2016512513A5 (enExample) | ||
| JP2012517449A5 (enExample) | ||
| JP2013542205A5 (enExample) | ||
| JP2019521180A5 (enExample) | ||
| JP2009515901A5 (enExample) |